Goldman Sachs Remains a Buy on Merck & Co (MRK), Sets a $99.00 PT

Merck & Co., Inc. (NYSE:MRK) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Analyst Asad Haider from Goldman Sachs maintained a Buy rating on Merck & Co., Inc. (NYSE:MRK) on June 11 with a $99.00 price target. The analyst supported the optimistic rating with the company’s ongoing initiatives and strategic positioning, stating that management is actively conducting constructive discussions with the administration about drug pricing. This reflects Merck & Co., Inc.’s (NYSE:MRK) proactive approach to addressing challenges in the industry, according to the analyst.

Haider considered this dialogue a positive step that could benefit both the company and the broader biopharma sector by attaining favorable outcomes. Merck & Co., Inc. (NYSE:MRK) thus ranks fifth on our list of the top drug stocks to invest in according to hedge funds.

The analyst also reasoned that Merck & Co., Inc. (NYSE:MRK) has a key focus on strategic business development and innovation, including potential M&As, lending it a strong position for future growth and supporting the Buy rating.

Merck & Co., Inc. (NYSE:MRK) is a biopharmaceutical company that delivers health solutions to advance the treatment and prevention of diseases in animals and people. Its Pharmaceutical segment offers vaccines and human health pharmaceutical products, which typically consist of therapeutic and preventive agents. Its Animal Health segment develops, discovers, manufactures, and markets a range of vaccines and veterinary pharmaceutical products.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.